Levy, Julia, Farag, Fady and Cole, John (2022). Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience. Breast Cancer Research and Treatment, 196 (1), 207-213. doi: 10.1007/s10549-022-06735-9
Journal Article: Endocrine therapy for early breast cancer: Updated review
Tremont, Alexander, Lu, Jonathan and Cole, John T. (2017). Endocrine therapy for early breast cancer: Updated review. Ochsner Journal, 17 (4), 405-411. doi: 10.1043/TOJ-17-0036
Journal Article: Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy
Jahangir, Eiman, Shah, Sangeeta, Shum, Kelly, Baxter, Caitlin, Fitzpatrick, Jill D., Cole, John, Gilliland, Yvonne and Polin, Nichole M. (2015). Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy. Southern Medical Journal, 108 (2), 71-78. doi: 10.14423/SMJ.0000000000000232
Levy, Julia, Farag, Fady and Cole, John (2022). Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience. Breast Cancer Research and Treatment, 196 (1), 207-213. doi: 10.1007/s10549-022-06735-9
Endocrine therapy for early breast cancer: Updated review
Tremont, Alexander, Lu, Jonathan and Cole, John T. (2017). Endocrine therapy for early breast cancer: Updated review. Ochsner Journal, 17 (4), 405-411. doi: 10.1043/TOJ-17-0036
Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy
Jahangir, Eiman, Shah, Sangeeta, Shum, Kelly, Baxter, Caitlin, Fitzpatrick, Jill D., Cole, John, Gilliland, Yvonne and Polin, Nichole M. (2015). Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy. Southern Medical Journal, 108 (2), 71-78. doi: 10.14423/SMJ.0000000000000232
Cancer stem cell and stromal microenvironment
Li, Li, Cole, John and Margolin, David A. (2013). Cancer stem cell and stromal microenvironment. Ochsner Journal, 13 (1), 109-118.
Lee, Chung-Gi, Das, Bikul, Lin, Tara L., Grimes, Chelsea, Zhang, Xin, Lavezzi, Tracey, Huang, Li, Cole, John, Yau, Lillian and Li, Li (2012). A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential. British Journal of Haematology, 158 (1), 79-90. doi: 10.1111/j.1365-2141.2012.09123.x
Pegylated arginase I: a potential therapeutic approach in T-ALL
Hernandez, Claudia P., Morrow, Kevin, Lopez-Barcons, Lluis A., Zabaleta, Jovanny, Sierra, Rosa, Velasco, Cruz, Cole, John and Rodriguez, Paulo C. (2010). Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood, 115 (25), 5214-5221. doi: 10.1182/blood-2009-12-258822
Chicken Sarcoma to Human Cancers: A Lesson in Molecular Therapeutics
Prakash, Om, Bardot, Stephen F. and Cole, John T. (2007). Chicken Sarcoma to Human Cancers: A Lesson in Molecular Therapeutics. Ochsner Journal, 7 (2), 61-64.
Perez, Edith A., Suman, Vera J., Fitch, Tom R., Mailliard, James A., Ingle, James N., Cole, John T., Veeder, Michael H., Flynn, Patrick J., Walsh, Daniel J. and Addo, Ferdinand K. (2005). A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology, 69 (2), 117-121. doi: 10.1159/000087813
Le Chevalier, T., Arriagada, R., Le Pechoux, C., Grunenwald, D., Dunant, A., Pignon, J. P., Tarayre, M., Abratt, R., Arriagada, R., Bergman, B., Gralla, R., Grunenwald, D., Le Chevalier, T., Orlowski, T., Papadakis, E., Pinel, M. I. Sathler, Araujo, C., Della Torre, H., de Solchaga, M. Masetto, Abdi, E., Blum, R., Ball, D., Basser, R., De Boer, R., Bishop, J., Brigham, B., Davis, S., Fox, D., Richardson, G. ... Wedel, H. (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New England Journal of Medicine, 350 (4), 351-360. doi: 10.1056/NEJMoa031644
Buckner, J. C., Schomberg, P. J., McGinnis, W. L., Cascino, T. L., Scheithauer, B. W., O'Fallon, J. R., Morton, R. F., Kuross, S. A., Mailliard, J. A., Hatfield, A. K., Cole, J. T., Steen, P. D. and Bernath, A. M. (2001). A Phase III study of radiation therapy plus carmustine with or without recombinant interferon-α in the treatment of patients with newly diagnosed high-grade glioma. Cancer, 92 (2), 420-433. doi: 10.1002/1097-0142(20010715)92:2<420::AID-CNCR1338>3.0.CO;2-3
Sepsis due to coryneform group A-4 in an immunocompromised host
Bizette, G. A., Kemmerly, S. A., Cole, J. T., Bradford, H. B. and Peltier, B. H. (1995). Sepsis due to coryneform group A-4 in an immunocompromised host. Clinical Infectious Diseases, 21 (5), 1334-1336. doi: 10.1093/clinids/21.5.1334
SPLENECTOMY IN THE HIV-INFECTED PATIENT - REPLY
COLE, JT and FLAUM, MA (1993). SPLENECTOMY IN THE HIV-INFECTED PATIENT - REPLY. Southern Medical Journal, 86 (8), 980-980. doi: 10.1097/00007611-199308000-00032
Cole, J. T. and Flaum, M. A. (1992). Postsplenectomy infections. Southern Medical Journal, 85 (12), 1220-1226. doi: 10.1097/00007611-199212000-00014
Bhalla, K., Birkhofer, M., Bhalla, M., Lutzky, J., Hindenburg, A., Cole, J. and Ince, C. (1991). A Phase I study of a combination of allopurinol, 5-fluorouracil and leucovorin followed by hydroxyurea in patients with advanced gastrointestinal and breast cancer. American Journal of Clinical Oncology - Cancer Clinical Trials, 14 (6), 509-513. doi: 10.1097/00000421-199112000-00009
Acute myelomonocytic leukemia presenting as a benign-appearing cutaneous eruption
Horlick, Howard P., Silvers, David N., Knobler, Elizabeth H. and Cole, John T. (1990). Acute myelomonocytic leukemia presenting as a benign-appearing cutaneous eruption. Archives of Dermatology, 126 (5), 653-656. doi: 10.1001/archderm.126.5.653
The effect in vitro of 2'-deoxycytidine on the metabolism and cytotoxicity of 2',3'-dideoxycytidine
Bhalla, K. N., Li, G. R., Grant, S., Cole, J. T., Maclaughlin, W. W. and Volsky, D. J. (1990). The effect in vitro of 2'-deoxycytidine on the metabolism and cytotoxicity of 2',3'-dideoxycytidine. Aids, 4 (5), 427-431. doi: 10.1097/00002030-199005000-00008
Bhalla, K., Birkhofer, M., Li, G. R., Grant, S., Maclaughlin, W., Cole, J., Graham, G. and Volsky, D. J. (1989). 2'-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3'-azido-3'-deoxythymidine with preservation of antiretroviral activity. Blood, 74 (6), 1923-1928.
Phase I clinical and pharmacologic study of deoxycytidine
Bhalla, K., Birkhofer, M., Grant, S., Baker, M., Maclaughlin, W., Cole, J. and Graham, G. (1988). Phase I clinical and pharmacologic study of deoxycytidine. Leukemia, 2 (10), 709-710.
Bhalla, K., Cole, J., Maclaughlin, W., Arlin, Z., Baker, M., Graham, G. and Grant, S. (1987). Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells. Leukemia, 1 (12), 814-819.
Bhalla, K., Maclaughlin, W., Cole, J., Arlin, Z., Baker, M., Graham, G. and Grant, S. (1987). Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity. Blood, 70 (2), 568-571.
Bhalla, K., Cole, J., Maclaughlin, W., Baker, M., Arlin, Z., Graham, G. and Grant, S. (1986). Deoxycytidine stimulates the in vitro growth of normal CFU-GM and reverses the negative regulatory effects of acidic isoferritin and prostaglandin E1. Blood, 68 (5), 1136-1141.
L-arginine depletion by PEG-arginase I, a new potential therapy for acute lymphoblastic leukemia
Ramos, Ofelia Crombet, Hernandez, Claudia, Morrow, Kevin, Cole, John T. and Rodriguez, Paulo (2012). L-arginine depletion by PEG-arginase I, a new potential therapy for acute lymphoblastic leukemia. 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.
Jahangir, K. S., Varughese, S., Lin, T. L., Boulmay, B. C., Rigby, P. G. and Cole, J. T. (2011). B12 DEFICIENCY REVISITED. Southern Regional Meeting, New Orleans La, Feb 17-19, 2011. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Varughese, S., Jahangir, K. S., Lin, T., Boulmay, B., Rigby, P. and Cole, J. T. (2011). MY COLLAR BONE HURTS!. Southern Regional Meeting, New Orleans La, Feb 17-19, 2011. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Velcheti, Vamsidhar, Li, Li, Philips, Joseph, Fuloria, Jyotsna, Rodwig, Francis R., Cole, John T., Samaniego, Felipe and Prakash, Om (2009). Prelinical Evaluation of Lyn Kinase Inhibition for the Treatment of B Cell Chronic Lymphocytic Leukemia (B-CLL). 51st Annual Meeting of the American-Society-of-Hematology, New Orleans La, Dec 05-08, 2009. WASHINGTON: AMER SOC HEMATOLOGY.
Velcheti, Vamsidhar, Tamma, Srikanth, Larned, Zoe L., Fuloria, Jyotsna, Li, Li, Rodwig, Francis R., Cole, John T., Samaniego, Felipe and Prakash, Om (2008). Protein Kinase C-Epsilon Is An Important Component of the Lyn Kinase Signaling Pathway in the Apoptotic Resistance of B-Chronic Lymphocytic Leukemia Cells. 50th Annual Meeting of the American-Society-of-Hematology, San Francisco Ca, Dec 06-09, 2008. WASHINGTON: AMER SOC HEMATOLOGY.
Velcheti, V., Thumma, V., Matrana, M. and Cole, J. T. (2008). Differences in treatment and outcomes of non-small cell lung cancer (NSCLC) in Louisiana compared to the rest of the United States: A National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) analysis. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2008.26.15_suppl.17507
Bhalla, K., Maclaughlin, W., Cole, J., Arlin, Z., Birkhofer, M. and Graham, G. (1988). Continuously Administered 2',2'-Difluorodeoxycytidine (Dfdc) and Deoxycytidine (Dcyd) - a Potentially Selective Cyto-Toxic Regimen Toward Human-Leukemic Myeloid Progenitors in Culture. -, -, -. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.
Phase-I Study of Deoxycytidine Administered as a 120 Hour Continuous Intravenous-Infusion
Bhalla, K., Grant, S., Maclaughlin, W., Cole, J., Birkhofer, M., Kappel, B., Kritz, A. and Graham, G. (1988). Phase-I Study of Deoxycytidine Administered as a 120 Hour Continuous Intravenous-Infusion. -, -, -. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.
MacLaughlin, W., Cole, J., Grant, S. and Bhalla, K. (1987). High-Dose of Deoxycytidine Analogs and Deoxycytidine - a Potentially Selective Cytotoxic Regimen Against Breast-Cancer Cells (47D) in Culture. -, -, -. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.
Bhalla, K., Maclaughlin, W., Cole, J., Arlin, Z., Baker, M., Graham, G. and Grant, S. (1987). Mechanism Underlying the Selective Cytotoxicity of High-Dose Ara-C and Deoxycytidine Toward Human-Leukemic Myeloid Progenitor Cells. -, -, -. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.
Bhalla, K., Maclaughlin, W., Cole, J., Arlin, Z., Baker, M., Graham, G. and Grant, S. (1986). Continuously Administered High-Dose Ara-C and Deoxycytidine - a Potentially Selective Cytotoxic Regimen Toward Human-Leukemic Myeloid Progenitors in Culture. -, -, -. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.
MacLaughlin, W., Bhalla, K., Cole, J. and Grant, S. (1986). Differential Reversal of Deoxycytidine Analog Mediated Cytotoxicity by Deoxycytidine in Cultured Normal and Leukemic Myeloid Progenitors. -, -, -. THOROFARE: SLACK INC.